S
Subodh Verma
Researcher at University of Toronto
Publications - 451
Citations - 27354
Subodh Verma is an academic researcher from University of Toronto. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 68, co-authored 355 publications receiving 17675 citations. Previous affiliations of Subodh Verma include Charité & University of Calgary.
Papers
More filters
Journal ArticleDOI
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J.V. McMurray,Scott D. Solomon,Silvio E. Inzucchi,Lars Køber,Mikhail Kosiborod,Felipe Martinez,Piotr Ponikowski,Marc S. Sabatine,Marc S. Sabatine,Inder S. Anand,Jan Bělohlávek,Michael Böhm,Chern-En Chiang,Chern-En Chiang,Vijay K. Chopra,Rudolf A. de Boer,Akshay S. Desai,Mirta Diez,Jarosław Drożdż,Andrej Dukát,Junbo Ge,Jonathan G. Howlett,Jonathan G. Howlett,Tzvetana Katova,Masafumi Kitakaze,Charlotta Ljungman,Béla Merkely,Jose C. Nicolau,Eileen O'Meara,Mark C. Petrie,Pham Nguyen Vinh,Morten Schou,Tereshchenko Sn,Subodh Verma,Claes Held,David L. DeMets,Kieran F. Docherty,Pardeep S. Jhund,Olof Bengtsson,Mikaela Sjöstrand,AM Langkilde +40 more
TL;DR: Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than amongThose who received placebo, regardless of the presence or absence of diabetes.
Journal ArticleDOI
Empagliflozin in heart failure with a preserved ejection fraction
Stefan D. Anker,Javed Butler,Gerasimos Filippatos,João Pedro Ferreira,Edimar Bocchi,Michael Böhm,Hans-Peter Brunner-La Rocca,Dong-Ju Choi,Vijay K. Chopra,Eduardo Chuquiure-Valenzuela,Nadia Giannetti,Juan Esteban Gomez-Mesa,Stefan Janssens,James L. Januzzi,Jose R Gonzalez-Juanatey,Bela Merkely,Stephen J. Nicholls,Sergio V. Perrone,Ileana L. Piña,Piotr Ponikowski,Michele Senni,David K.L. Sim,Jindrich Spinar,Iain Squire,Stefano Taddei,Hiroyuki Tsutsui,Subodh Verma,Dragos Vinereanu,Jian Zhang,Peter E. Carson,Carolyn Su Ping Lam,Nikolaus Marx,Cordula Zeller,Naveed Sattar,Waheed Jamal,Sven Schnaidt,Janet Schnee,Martina Brueckmann,Stuart J. Pocock,Faiez Zannad,Milton Packer,EMPEROR-Preserved Trial Investigators +41 more
TL;DR: In this paper, a double-blind trial was conducted to evaluate the effect of empagliflozin on the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction.
Journal ArticleDOI
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt,Michael Szarek,P. Gabriel Steg,Christopher P. Cannon,Lawrence A. Leiter,Darren K. McGuire,Julia B. Lewis,Matthew C. Riddle,Adriaan A. Voors,Marco Metra,Lars H. Lund,Michel Komajda,Jeffrey M. Testani,Christopher S. Wilcox,Piotr Ponikowski,Renato D. Lopes,Subodh Verma,Pablo Lapuerta,Bertram Pitt +18 more
TL;DR: In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo.
Journal ArticleDOI
New markers of inflammation and endothelial cell activation: Part I.
Paul E. Szmitko,Chao-Hung Wang,Richard D. Weisel,John R. de Almeida,Todd J. Anderson,Subodh Verma +5 more
TL;DR: This review article will provide a brief overview of the link between inflammation, endothelial dysfunction, and atherosclerosis and will begin highlighting emerging inflammatory mediators of endothelial cell (EC) activation, a discussion that will be continued in Part 2.
Journal ArticleDOI
Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein
Subodh Verma,Shu-Hong Li,Mitesh V. Badiwala,Richard D. Weisel,Paul W.M. Fedak,Ren-Ke Li,Bikramjit Dhillon,Donald A.G. Mickle +7 more
TL;DR: The role of the potent endothelium-derived vasoactive factor endothelin-1 (ET-1) and the inflammatory cytokine interleukin-6 (IL-6) as mediators ofCRP-induced proatherogenic processes is examined and Bosentan may be useful in decreasing CRP-mediated vascular disease.